US biotech Amgen (Nasdaq: AMGN) closed 1.6% up on Monday at $165.09 after news of further progress relating to its monoclonal antibody, Xgeva (denosumab).
The US Food and Drug Administration (FDA) has accepted the Xgeva (denosumab) supplemental Biologics License Application (sBLA) that seeks to expand the currently-approved indication for the prevention of fractures and other skeletal-related events in patients with bone metastases from solid tumors, to include patients with multiple myeloma. A Prescription Drug User Fee Act (PDUFA) action date has been set by the FDA of February 3, 2018.
Sean Harper, executive vice president of research and development at Amgen, said: “Multiple myeloma patients with fractures and other bone complications have a very poor prognosis.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze